Anu Kantele-Häkkinen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2396322/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Extended-spectrum beta-lactamase-producing strains among diarrhoeagenic <i>Escherichia coli</i> —prospective traveller study with literature review. Journal of Travel Medicine, 2022, 29, .	1.4	13
2	Three-dose versus four-dose primary schedules for tick-borne encephalitis (TBE) vaccine FSME-immun for those aged 50Âyears or older: A single-centre, open-label, randomized controlled trial. Vaccine, 2022, 40, 1299-1305.	1.7	8
3	European hospitals as source of multidrug-resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad. Journal of Travel Medicine, 2022, 29, .	1.4	8
4	International travel and travelers' diarrhea – Increased risk of urinary tract infection. Travel Medicine and Infectious Disease, 2022, 48, 102331.	1.5	2
5	Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients. Frontiers in Immunology, 2022, 13, 869990.	2.2	40
6	Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants. Nature Communications, 2022, 13, 2476.	5.8	43
7	Scent dogs in detection of COVID-19: triple-blinded randomised trial and operational real-life screening in airport setting. BMJ Global Health, 2022, 7, e008024.	2.0	20
8	SARS-CoV-2 infections among healthcare workers at Helsinki University Hospital, Finland, spring 2020: Serosurvey, symptoms and risk factors. Travel Medicine and Infectious Disease, 2021, 39, 101949.	1.5	28
9	A 10-Minute "Mix and Read―Antibody Assay for SARS-CoV-2. Viruses, 2021, 13, 143.	1.5	16
10	Bacterial, viral and parasitic pathogens analysed by qPCR: Findings from a prospective study of travellers' diarrhoea. Travel Medicine and Infectious Disease, 2021, 40, 101957.	1.5	13
11	Dynamics of intestinal multidrug-resistant bacteria colonisation contracted by visitors to a high-endemic setting: a prospective, daily, real-time sampling study. Lancet Microbe, The, 2021, 2, e151-e158.	3.4	45
12	Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays. Viruses, 2021, 13, 996.	1.5	14
13	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nature Communications, 2021, 12, 3991.	5.8	241
14	Characterization of low-density granulocytes in COVID-19. PLoS Pathogens, 2021, 17, e1009721.	2.1	51
15	Prevalence of diarrhoeal pathogens among children under five years of age with and without diarrhoea in Guinea-Bissau. PLoS Neglected Tropical Diseases, 2021, 15, e0009709.	1.3	17
16	Import of multidrug-resistant bacteria from abroad through interhospital transfers, Finland, 2010–2019. Eurosurveillance, 2021, 26, .	3.9	7
17	Revisiting travellers' diarrhoea justifying antibiotic treatment: prospective study. Journal of Travel Medicine, 2021, 28,	1.4	6
18	Hospital admissions of refugees, asylum seekers and undocumented migrants: Ten-year retrospective study. Travel Medicine and Infectious Disease, 2021, 44, 102186.	1.5	0

#	Article	IF	CITATIONS
19	COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets. Thrombosis Research, 2021, 208, 129-137.	0.8	12
20	A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies. Microbiology Spectrum, 2021, 9, e0113121.	1.2	18
21	Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections. Viruses, 2021, 13, 2489.	1.5	20
22	APOE ε4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study. Acta Neuropathologica Communications, 2021, 9, 199.	2.4	55
23	Despite Predominance of Uropathogenic/Extraintestinal Pathotypes Among Travel-acquired Extended-spectrum β-Lactamaseâ€ ^{°°} producing Escherichia coli, the Most Commonly Associated Clinical Manifestation Is Travelers' Diarrhea. Clinical Infectious Diseases, 2020, 70, 210-218.	2.9	24
24	Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. Cell Reports Medicine, 2020, 1, 100078.	3.3	160
25	Clinical aspects of heat-labile and heat-stable toxin-producing enterotoxigenic Escherichia coli: A prospective study among Finnish travellers. Travel Medicine and Infectious Disease, 2020, 38, 101855.	1.5	16
26	Neuropathologic features of four autopsied COVIDâ€19 patients. Brain Pathology, 2020, 30, 1012-1016.	2.1	152
27	Discovery and development of safe-in-man broad-spectrum antiviral agents. International Journal of Infectious Diseases, 2020, 93, 268-276.	1.5	169
28	Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic <i>Escherichia coli</i> (DEC). Annals of the Rheumatic Diseases, 2020, 79, 605-611.	0.5	12
29	Effects of Environmental Factors on Severity and Mortality of COVID-19. Frontiers in Medicine, 2020, 7, 607786.	1.2	40
30	Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Eurosurveillance, 2020, 25, .	3.9	226
31	Stand-by antibiotics encourage unwarranted use of antibiotics for travelers' diarrhea: A prospective study. Travel Medicine and Infectious Disease, 2019, 27, 64-71.	1.5	23
32	Human Monkeypox. Infectious Disease Clinics of North America, 2019, 33, 1027-1043.	1.9	432
33	Low Temperature and Low UV Indexes Correlated with Peaks of Influenza Virus Activity in Northern Europe during 2010–2018. Viruses, 2019, 11, 207.	1.5	81
34	Seasonal influenza vaccines induced high levels of neutralizing cross-reactive antibody responses against different genetic group influenza A(H1N1)pdm09 viruses. Vaccine, 2019, 37, 2731-2740.	1.7	2
35	Import of community-associated, methicillin-resistant Staphylococcus aureus to Europe through skin and soft-tissue infection in intercontinental travellers, 2011–2016. Clinical Microbiology and Infection, 2019, 25, 739-746.	2.8	35
36	Travellers as sentinels of chikungunya epidemics: a family cluster among Finnish travellers to Koh Lanta, Thailand, January 2019. Eurosurveillance, 2019, 24, .	3.9	13

#	Article	IF	CITATIONS
37	Dientamoeba fragilis – the most common intestinal protozoan in the Helsinki Metropolitan Area, Finland, 2007 to 2017. Eurosurveillance, 2019, 24, .	3.9	15
38	Author's response: False-positive results with rapid diagnostic test for dengue in Thailand. Eurosurveillance, 2019, 24, .	3.9	0
39	A prospective study of travellers' diarrhoea: analysis of pathogen findings by destination in various (sub)tropical regions. Clinical Microbiology and Infection, 2018, 24, 908.e9-908.e16.	2.8	35
40	Emerging infections—an increasingly important topic: review by the Emerging Infections Task Force. Clinical Microbiology and Infection, 2018, 24, 369-375.	2.8	44
41	Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research, 2018, 154, 174-182.	1.9	64
42	Despite antibiotic treatment of travellers' diarrhoea, pathogens are found in stools from half of travellers at return. Travel Medicine and Infectious Disease, 2018, 23, 49-55.	1.5	15
43	Circulating pathogen-specific plasmablasts in female patients with upper genital tract infection. Journal of Reproductive Immunology, 2018, 126, 69-75.	0.8	0
44	Travellers' diarrhoea: Impact of TD definition and control group design on study results. Travel Medicine and Infectious Disease, 2018, 24, 37-43.	1.5	15
45	Destination specific risks of acquisition of notifiable food- and waterborne infections or sexually transmitted infections among Finnish international travellers, 1995–2015. Travel Medicine and Infectious Disease, 2018, 25, 35-41.	1.5	12
46	Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) among travellers to Africa: destination-specific data pooled from three European prospective studies. BMC Infectious Diseases, 2018, 18, 341.	1.3	14
47	High rates of meticillin-resistant Staphylococcus aureus among asylum seekers and refugees admitted to Helsinki University Hospital, 2010 to 2017. Eurosurveillance, 2018, 23, .	3.9	23
48	Fluoroquinolone antibiotic users select fluoroquinolone-resistant ESBL-producing Enterobacteriaceae (ESBL-PE) – Data of a prospective traveller study. Travel Medicine and Infectious Disease, 2017, 16, 23-30.	1.5	55
49	Patients hospitalized abroad as importers of multiresistant bacteria—a cross-sectional study. Clinical Microbiology and Infection, 2017, 23, 673.e1-673.e8.	2.8	41
50	Travel-acquired ESBL-producing Enterobacteriaceae: impact of colonization at individual and community level. Journal of Travel Medicine, 2017, 24, S29-S34.	1.4	109
51	Multiplex PCR detection of <i>Cryptosporidium</i> sp, <i>Giardia lamblia</i> and <i>Entamoeba histolytica</i> directly from dried stool samples from Guinea-Bissauan children with diarrhoea. Infectious Diseases, 2017, 49, 655-663.	1.4	19
52	A closer look at travellers' infections abroad: Finnish nationwide data with incidences, 2010 to 2012. Travel Medicine and Infectious Disease, 2017, 15, 29-36.	1.5	12
53	Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines. Expert Review of Vaccines, 2017, 16, 1029-1043.	2.0	18
54	Specific and Crossâ€reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine. Scandinavian Journal of Immunology, 2017, 86, 207-215.	1.3	6

#	Article	IF	CITATIONS
55	Increased Risk for ESBL-Producing Bacteria from Co-administration of Loperamide and Antimicrobial Drugs for Travelers' Diarrhea1. Emerging Infectious Diseases, 2016, 22, 117-120.	2.0	55
56	Acute Human Inkoo and Chatanga Virus Infections, Finland. Emerging Infectious Diseases, 2016, 22, 810-817.	2.0	38
57	Combined Expression of IFN-γ, IL-17, and IL-4 mRNA by Recall PBMCs Moderately Discriminates Active Tuberculosis from Latent Mycobacterium tuberculosis Infection in Patients with Miscellaneous Inflammatory Underlying Conditions. Frontiers in Immunology, 2016, 7, 239.	2.2	6
58	Immune Defense in Upper Airways: A Single-Cell Study of Pathogen-Specific Plasmablasts and Their Migratory Potentials in Acute Sinusitis and Tonsillitis. PLoS ONE, 2016, 11, e0154594.	1.1	14
59	Systematic review of loperamide: No proof of antibiotics being superior to loperamide in treatment of mild/moderate travellers' diarrhoea. Travel Medicine and Infectious Disease, 2016, 14, 299-312.	1.5	35
60	Travelers' health problems and behavior: prospective study with post-travel follow-up. BMC Infectious Diseases, 2016, 16, 328.	1.3	70
61	Protein profiling of nasopharyngeal aspirates of hospitalized and outpatients revealed cytokines associated with severe influenza A(H1N1)pdm09 virus infections: A pilot study. Cytokine, 2016, 86, 10-14.	1.4	7
62	Emerging diseases—the monkeypox epidemic in the Democratic Republic of the Congo. Clinical Microbiology and Infection, 2016, 22, 658-659.	2.8	45
63	Prospective study of pathogens in asymptomatic travellers and those with diarrhoea: aetiological agents revisited. Clinical Microbiology and Infection, 2016, 22, 535-541.	2.8	45
64	Complete Genome Sequences of Influenza A/H1N1 Strains Isolated from Patients during the 2013-2014 Epidemic Season in Finland. Genome Announcements, 2015, 3, .	0.8	3
65	Comparative Analysis of Whole-Genome Sequences of Influenza A(H1N1)pdm09 Viruses Isolated from Hospitalized and Nonhospitalized Patients Identifies Missense Mutations That Might Be Associated with Patient Hospital Admissions in Finland during 2009 to 2014. Genome Announcements, 2015, 3, .	0.8	8
66	Skin and soft tissue infections in intercontinental travellers and the import of multi-resistant Staphylococcus aureus to Europe. Clinical Microbiology and Infection, 2015, 21, 567.e1-567.e10.	2.8	71
67	Antimicrobials Increase Travelers' Risk of Colonization by Extended-Spectrum Betalactamase-Producing Enterobacteriaceae. Clinical Infectious Diseases, 2015, 60, 837-846.	2.9	241
68	Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly. Vaccine, 2015, 33, 451-458.	1.7	16
69	Should close contacts of returning travellers with typhoid fever be protected by vaccination?. Vaccine, 2015, 33, 1419-1421.	1.7	0
70	As Far as Travelers' Risk of Acquiring Resistant Intestinal Microbes Is Considered, No Antibiotics (Absorbable or Nonabsorbable) Are Safe. Clinical Infectious Diseases, 2015, 60, 1872-1873.	2.9	6
71	A call to restrict prescribing antibiotics for travellers' diarrhea – Travel medicine practitioners can play an active role in preventing the spread of antimicrobial resistance. Travel Medicine and Infectious Disease, 2015, 13, 213-214.	1.5	20
72	Reply to Lauhio et al. Clinical Infectious Diseases, 2015, 61, 1031.2-1032.	2.9	0

#	Article	IF	CITATIONS
73	Predominance of dfrG as determinant of trimethoprim resistance in imported Staphylococcus aureus. Clinical Microbiology and Infection, 2015, 21, 1095.e5-1095.e9.	2.8	35
74	Granzyme B mediated function of Parvovirus B19â€specific CD4 ⁺ T cells. Clinical and Translational Immunology, 2015, 4, e39.	1.7	19
75	Differences in Homing Potentials ofStreptococcus pneumoniae–Specific Plasmablasts in Pneumococcal Pneumonia and After Pneumococcal Polysaccharide and Pneumococcal Conjugate Vaccinations. Journal of Infectious Diseases, 2015, 212, 1279-1287.	1.9	8
76	The Vero cell-derived, inactivated, SA ₁₄ -14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis. Expert Review of Vaccines, 2015, 14, 1167-1179.	2.0	30
77	An autochthonous case of cystic echinococcosis in Finland, 2015. Eurosurveillance, 2015, 20, .	3.9	8
78	Illness and injury of travellers abroad: Finnish nationwide data from 2010 to 2012, with incidences in various regions of the world. Eurosurveillance, 2015, 20, .	3.9	20
79	Reduced cross-protection against influenza A(H3N2) subgroup 3C.2a and 3C.3a viruses among Finnish healthcare workers vaccinated with 2013/14 seasonal influenza vaccine. Eurosurveillance, 2015, 20, 21028.	3.9	11
80	Illness and injury of travellers abroad: Finnish nationwide data from 2010 to 2012, with incidences in various regions of the world. Eurosurveillance, 2015, 20, 15-26.	3.9	11
81	Genetic Instability of Influenza pH1N1 Viruses. Genome Announcements, 2014, 2, .	0.8	5
82	Influenza pH1N1 Virus Accumulated H275Y Mutation in Neuraminidase during Propagation in MDCK Cells. Genome Announcements, 2014, 2, .	0.8	5
83	Full-Genome Sequences of Influenza A(H1N1)pdm09 Viruses Isolated from Finnish Patients from 2009 to 2013. Genome Announcements, 2014, 2, .	0.8	12
84	Crossâ€Reactive Immune Response Induced by the Vi Capsular Polysaccharide Typhoid Vaccine Against <i>Salmonella</i> Paratyphi Strains. Scandinavian Journal of Immunology, 2014, 79, 222-229.	1.3	11
85	Antimalarial Prophylaxis—Efficacy or Effectiveness?. Journal of Travel Medicine, 2014, 21, 137-138.	1.4	3
86	High number of diarrhoeal co-infections in travellers to Benin, West Africa. BMC Infectious Diseases, 2014, 14, 81.	1.3	35
87	Approach to non-invasive sampling in dengue diagnostics: Exploring virus and NS1 antigen detection in saliva and urine of travelers with dengue. Journal of Clinical Virology, 2014, 61, 353-358.	1.6	45
88	Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae. Vaccine, 2014, 32, 544-551.	1.7	10
89	Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Travel Medicine and Infectious Disease, 2014, 12, 134-142.	1.5	67
90	Full-Genome Sequences of Influenza H3N2 Virus Strains Isolated from Finnish Patients during the 2012-2013 Epidemic Season. Genome Announcements, 2014, 2, .	0.8	1

#	Article	IF	CITATIONS
91	A Quantitative Polymerase Chain Reaction Assay for Rapid Detection of 9 Pathogens Directly From Stools of Travelers With Diarrhea. Clinical Gastroenterology and Hepatology, 2013, 11, 1300-1307.e3.	2.4	61
92	Imported malaria in Finland 2003-2011: prospective nationwide data with rechecked background information. Malaria Journal, 2013, 12, 93.	0.8	10
93	Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: A two-year follow-up study. Vaccine, 2013, 32, 119-123.	1.7	27
94	Cytotoxic response persists in subjects treated for tuberculosis decades ago. BMC Infectious Diseases, 2013, 13, 573.	1.3	2
95	Antibody responses against influenza A(H1N1)pdm09 virus after sequential vaccination with pandemic and seasonal influenza vaccines in Finnish healthcare professionals. Influenza and Other Respiratory Viruses, 2013, 7, 431-438.	1.5	6
96	Cross-Protective Capacity of Japanese Encephalitis (JE) Vaccines Against Circulating Heterologous JE Virus Genotypes. Clinical Infectious Diseases, 2013, 56, 267-270.	2.9	60
97	Modification of Clearview Tuberculosis (TB) Enzyme-Linked Immunosorbent Assay for TB Patients Not Infected with HIV. Vaccine Journal, 2013, 20, 1479-1482.	3.2	16
98	Dengue in Travelers: Kinetics of Viremia and NS1 Antigenemia and Their Associations with Clinical Parameters. PLoS ONE, 2013, 8, e65900.	1.1	30
99	Head-to-Head Comparison of Humoral Immune Responses to Vi Capsular Polysaccharide and Salmonella Typhi Ty21a Typhoid Vaccines–A Randomized Trial. PLoS ONE, 2013, 8, e60583.	1.1	44
100	Obatoclax, Saliphenylhalamide, and Gemcitabine Inhibit Influenza A Virus Infection. Journal of Biological Chemistry, 2012, 287, 35324-35332.	1.6	80
101	A Single Dose of Vero Cell-Derived Japanese Encephalitis (JE) Vaccine (Ixiaro) Effectively Boosts Immunity in Travelers Primed With Mouse Brain-Derived JE Vaccines. Clinical Infectious Diseases, 2012, 55, 825-834.	2.9	40
102	Persistence of Diarrheal Pathogens Is Associated with Continued Recruitment of Plasmablasts in the Circulation. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	9
103	Immunosuppression Adversely Affects TST but Not IGRAs in Patients with Psoriasis or Inflammatory Musculoskeletal Diseases. International Journal of Rheumatology, 2012, 2012, 1-8.	0.9	17
104	Fever With Rash in Patients Returning From Popular Tourist Resort Phuket, Thailand: Dengue—or Measles?: Table 1. Journal of Travel Medicine, 2012, 19, 317-319.	1.4	3
105	<i>Plasmodium falciparum</i> —Malaria in Pregnant African Immigrants Often Goes Unrecognized. Journal of Travel Medicine, 2012, 19, 380-382.	1.4	5
106	Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination. Vaccine, 2012, 30, 6047-6053.	1.7	41
107	Live oral typhoid vaccine Salmonella Typhi Ty21a – A surrogate vaccine against non-typhoid salmonella?. Vaccine, 2012, 30, 7238-7245.	1.7	31
108	Chikungunya virus as a causative agent of fever of unknown origin in Finnish travellers to tropics. Journal of Clinical Virology, 2012, 54, 289-290.	1.6	4

#	Article	IF	CITATIONS
109	Trichodysplasia spinulosa-Associated Polyomavirus (TSV) and Merkel Cell Polyomavirus: Correlation between Humoral and Cellular Immunity Stronger with TSV. PLoS ONE, 2012, 7, e45773.	1.1	11
110	Pathogen-Specific Circulating Plasmablasts in Patients with Pneumonia. PLoS ONE, 2012, 7, e34334.	1.1	13
111	Travellers returning with measles from Thailand to Finland, April 2012: infection control measures. Eurosurveillance, 2012, 17, .	3.9	16
112	PS2-079 T-helper cell-mediated proliferation and cytokine responses against recombinant merkel cell polyomavirus-like particles. Cytokine, 2011, 56, 85.	1.4	0
113	Fever in Travelers Returning from Malariaâ€Endemic Areas: Don't Look for Malaria Only. Journal of Travel Medicine, 2011, 18, 239-244.	1.4	21
114	Identification of the five human Plasmodium species including P. knowlesi by real-time polymerase chain reaction. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 597-601.	1.3	24
115	Serodiagnosis of Primary Infections with Human Parvovirus 4, Finland. Emerging Infectious Diseases, 2011, 17, 79-82.	2.0	44
116	Review of Cases With the Emerging Fifth Human Malaria Parasite, Plasmodium knowlesi. Clinical Infectious Diseases, 2011, 52, 1356-1362.	2.9	168
117	Reply to Antinori et al. Clinical Infectious Diseases, 2011, 53, 849-850.	2.9	0
118	Humoral Immune Response to Keyhole Limpet Haemocyanin, the Protein Carrier in Cancer Vaccines. Clinical and Developmental Immunology, 2011, 2011, 1-6.	3.3	12
119	T-helper Cell-Mediated Proliferation and Cytokine Responses against Recombinant Merkel Cell Polyomavirus-Like Particles. PLoS ONE, 2011, 6, e25751.	1.1	13
120	Imported Malaria in Finland 1995 to 2008: An Overview of Surveillance, Travel Trends, and Antimalarial Drug Sales. Journal of Travel Medicine, 2010, 17, 400-404.	1.4	20
121	Expression of Homing Receptors on IgA1 and IgA2 Plasmablasts in Blood Reflects Differential Distribution of IgA1 and IgA2 in Various Body Fluids. Vaccine Journal, 2010, 17, 393-401.	3.2	80
122	Early diagnosis of dengue in travelers: Comparison of a novel real-time RT-PCR, NS1 antigen detection and serology. Journal of Clinical Virology, 2010, 47, 49-53.	1.6	105
123	PS2-59 In vitro evaluation of interferon gamma responses against recombinant merkel cell polyomavirus-like. Cytokine, 2010, 52, 62-63.	1.4	0
124	Skin reaction to vaccination already before injection. Vaccine, 2010, 28, 2157.	1.7	3
125	Do as I say, not as I do: Handwashing compliance of infectious diseases experts during influenza pandemic. American Journal of Infection Control, 2010, 38, 579-580.	1.1	2
126	Decreased numbers of circulating plasmablasts and differences in IgA1-plasmablast homing to skin in coeliac disease and dermatitis herpetiformis. Clinical and Experimental Immunology, 2009, 156, 535-541.	1.1	7

#	Article	IF	CITATIONS
127	Distinctive homing profile of pathogen-specific activated lymphocytes in human urinary tract infection. Clinical Immunology, 2008, 128, 427-434.	1.4	15
128	Monkey Malaria in a European Traveler Returning from Malaysia. Emerging Infectious Diseases, 2008, 14, 1434-1436.	2.0	82
129	Local Immune Response to Upper Urinary Tract Infections in Children. Vaccine Journal, 2008, 15, 412-417.	3.2	9
130	Unique Characteristics of the Intestinal Immune System as an Inductive Site after Antigen Reencounter. Journal of Infectious Diseases, 2005, 191, 312-317.	1.9	28
131	Cutaneous lymphocyte antigen expression on human effector B cells depends on the site and on the nature of antigen encounter. European Journal of Immunology, 2003, 33, 3275-3283.	1.6	37
132	P Fimbria–Specific B Cell Responses in Patients with Urinary Tract Infection. Journal of Infectious Diseases, 2003, 188, 1885-1891.	1.9	20
133	Increased Expression of Intercellular Adhesion Molecule-1 and Mucosal Adhesion Molecule α4β7 Integrin in Small Intestinal Mucosa of Adult Patients with Food Allergy. Clinical Immunology, 2001, 99, 353-359.	1.4	22
134	Induction of specific immune responses in the genital tract of women after oral or rectal immunization and rectal boosting with Salmonella typhi Ty 21a vaccine. Journal of Reproductive Immunology, 2001, 52, 61-75.	0.8	38
135	Homing potentials of circulating antibody-secreting cells after administration of oral or parenteral protein or polysaccharide vaccine in humans. Vaccine, 1999, 17, 229-236.	1.7	38
136	Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans. Journal of Immunology, 1999, 162, 5173-7.	0.4	97
137	Enteric Infections in an Endemic Area Induce a Circulating Antibodyâ€Secreting Cell Response with Homing Potentials to Both Mucosal and Systemic Tissues. Journal of Infectious Diseases, 1998, 177, 1594-1599.	1.9	16
138	Differences in Immune Responses Induced by Oral and Rectal Immunizations with <i>Salmonella typhi</i> Ty21a: Evidence for Compartmentalization within the Common Mucosal Immune System in Humans. Infection and Immunity, 1998, 66, 5630-5635.	1.0	149
139	Human peritoneal B-1 cells and the influence of continuous ambulatory peritoneal dialysis on peritoneal and peripheral blood mononuclear cell (PBMC) composition and immunoglobulin levels. Clinical and Experimental Immunology, 1997, 109, 356-361.	1.1	29
140	Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. Journal of Immunology, 1997, 158, 574-9.	0.4	118
141	Mucosally activated circulating human B cells in diarrhea express homing receptors directing them back to the gut. Gastroenterology, 1996, 110, 1061-1067.	0.6	65
142	Peripheral blood antibody-secreting cells in the evaluation of the immune response to an oral vaccine. Journal of Biotechnology, 1996, 44, 217-224.	1.9	31
143	Circulating Antibody Secreting Cells and Humoral Antibody Response after Parenteral Immunization with a Meningococcal Polysaccharide Vaccine. Scandinavian Journal of Infectious Diseases, 1996, 28, 53-58.	1.5	11
144	Circulating immunoglobulin-secreting cells are heterogeneous in their expression of maturation markers and homing receptors. Clinical and Experimental Immunology, 1996, 104, 525-530.	1.1	28

#	Article	IF	CITATIONS
145	Antibody-Secreting Cells in Acute Urinary Tract Infection as Indicators of Local Immune Response. Journal of Infectious Diseases, 1994, 169, 1023-1028.	1.9	29
146	Comparison of the human immune response to live oral, killed oral or killed parenteral Salmonella typhi TY21A vaccines. Microbial Pathogenesis, 1991, 10, 117-126.	1.3	51
147	Different profiles of the human immune response to primary and secondary immunization with an oral Salmonella typhi Ty21a vaccine. Vaccine, 1991, 9, 423-427.	1.7	56
148	Active immunity is seen as a reduction in the cell response to oral live vaccine. Vaccine, 1991, 9, 428-431.	1.7	49
149	Immune Response to Prolonged Intestinal Exposure to Antigen. Scandinavian Journal of Immunology, 1991, 33, 225-229.	1.3	26
150	Salmonella-Specific Antibodies in Reactive Arthritis. Journal of Infectious Diseases, 1991, 164, 1141-1148.	1.9	53
151	Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine, 1990, 8, 321-326.	1.7	128
152	Antibody-secreting cell responses after vaccination with parenteral killed, oral killed or oral live vaccine. , 1990, , 353-354.		0
153	Specific Immunoglobulin-Secreting Human Blood Cells After Peroral Vaccination Against Salmonella typhi. Journal of Infectious Diseases, 1986, 153, 1126-1131.	1.9	121